Molecular Partners AG (XSWX:MOLN) Research & Development: CHF37.72 Mil (TTM As of Mar. 2026)


XSWX:MOLN Molecular Partners AG XSWX:MOLN
29 GF Score
Price CHF3.12
GF Value CHF0.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Research & Development?

Molecular Partners AG XSWX:MOLN +0.65% 29 Research & Development is CHF37.72 Mil as of Mar. 2026. GuruFocus rates XSWX:MOLN with a GF Score™ of 29/100 and a GF Value™ of CHF0.37 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Molecular Partners AG's Research & Development for the three months ended in Mar. 2026 was CHF9.45 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was CHF37.72 Mil.

Molecular Partners AG  (XSWX:MOLN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Molecular Partners AG Research & Development Related Terms

Molecular Partners AG Research & Development Historical Data

* Premium members only.

The historical data trend for Molecular Partners AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG Research & Development Chart

Molecular Partners AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.72 50.75 48.78 48.60 40.19

Molecular Partners AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.92 10.71 8.33 9.24 9.45
XSWX:MOLN
29GF Score
Molecular Partners AG XSWX:MOLN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecular Partners AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF37.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF37.72 Mil mean?
Molecular Partners AG (XSWX:MOLN) has a Research & Development of CHF37.72 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Molecular Partners AG and its competitors.
Is Molecular Partners AG's Research & Development too high?
Molecular Partners AG's current Research & Development is CHF37.72 Mil. Overall, Molecular Partners AG has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Research & Development compare to VRTX and REGN?
Molecular Partners AG's Research & Development of CHF37.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current Research & Development is CHF37.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (XSWX:MOLN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF0.37, compared to a current price of CHF3.12 — trading 743.2% above its estimated fair value. The current Research & Development is CHF37.72 Mil. Molecular Partners AG's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Molecular Partners AG (XSWX:MOLN), the current Research & Development is CHF37.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of CHF3.12 is trading 743.2% above its estimated GF Value™ of CHF0.37. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for XSWX:MOLN:

  • Research & Development: CHF37.72 Mil
  • GF Value™: CHF0.37 vs. price of CHF3.12 (743.2% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score

Get the complete analysis for XSWX:MOLN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.12
Price
CHF0.37
GF Value